FDA grants Breakthrough designation for BI 1482694 in lung cancer
21 December 2015 | By Victoria White
BI 1482694 is Boehringer Ingelheim’s 3rd-generation, epidermal growth factor receptor mutation-specific tyrosine kinase inhibitor...
List view / Grid view
21 December 2015 | By Victoria White
BI 1482694 is Boehringer Ingelheim’s 3rd-generation, epidermal growth factor receptor mutation-specific tyrosine kinase inhibitor...
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
14 December 2015 | By Victoria White
The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12...
26 November 2015 | By Victoria White
Idarucizumab (Praxbind) rapidly and specifically reverses the anticoagulant effects of dabigatran etexilate (Pradaxa) in cases of emergency surgery /urgent procedures or in uncontrolled bleeding...
13 November 2015 | By Victoria White
A post-marketing surveillance study showed that treatment with Ofev in the real-world clinical setting had a safety profile consistent with that observed in clinical trials...
3 November 2015 | By Victoria White
BI 1482694 is a novel, third-generation, oral, irreversible EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with T790M mutations...
28 October 2015 | By Victoria White
Boehringer Ingelheim today announced new data from post-hoc analyses of studies of Spiolto Respimat and a Phase I trial of its adalimumab biosimilar candidate...
19 October 2015 | By Victoria White
Praxbind is indicated for patients treated with Pradaxa, when reversal of the anticoagulant effects of Pradaxa is needed for emergency surgery or in uncontrolled bleeding...
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
30 September 2015 | By Victoria White
The results confirm that Ofev has a long-term effect on slowing IPF disease progression and has a manageable side effect profile...
25 September 2015 | By Victoria White
Idarucizumab is intended for use in patients treated with dabigatran who require immediate anticoagulant reversal prior to urgent procedures or in case of uncontrolled bleeding...
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
16 September 2015 | By Victoria White
It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older...
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
1 September 2015 | By Charlotte Batchelor
Four grants will be awarded to independent research projects, focused on improving patient outcomes in thromboembolic diseases